0

Anti-Venom Market by Type and Geography - Forecast and Analysis 2022-2026

  • Published: Jan 2022
  • Pages: 120
  • SKU: IRTNTR71967
Technavio

Purchase this report now and if we publish a new version within 90 days, we will send you a free copy.

Safe and Secure SSL Encrypted
  • 2500.00
  • USD

The anti-venom market share is expected to increase by USD 481.51 million from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 7.82%.

This anti-venom market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers anti-venom market segmentation by type (polyvalent anti-venom, monovalent anti-venom, and other anti-venom types) and geography (North America, Asia, Europe, and ROW). The anti-venom market report also offers information on several market vendors, including Bharat Serums and Vaccines Ltd., Boehringer Ingelheim International GmbH, CSL Ltd., Haffkine bio pharmaceutical Corp. Ltd., Merck KGaA, Pfizer Inc., Rare Disease Therapeutics Inc., SERB Sarl, Serum Institute of India Pvt. Ltd., and VINS Bioproducts Ltd. among others.

What will the Anti-Venom Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Anti-Venom Market Size for the Forecast Period and Other Important Statistics

 

Anti-Venom Market: Key Drivers and Challenges

The rising prevalence of venomous bites and stings is notably driving the anti-venom market growth, although factors such as high cost of available anti-venoms may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the anti-venom industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Anti-Venom Market Driver

The healthcare and biotechnology industry is witnessing significant demand from developing economies globally. The key factor that drives the growth of the anti-venom market is the demand for anti-venom treatment being the only authorized treatment for snakebites. Destroying forest lands for agricultural and housing purposes has increased the proximity of human beings to poisonous insects and animals, which, in turn, increases the prevalence of venomous bites. The high prevalence of snakebites, scorpion bites, and other animal or insect bites, such as fish stings, is driving the growth of the anti-venom market.

Key Anti-Venom Market Challenge

The total cost of tendinitis treatment is considerably high, as the total cost includes clinical trials, legal costs, hospital fees, and US FDA fees. Furthermore, the process of making anti-venom is quite complicated. It involves injecting sheep with snake venom and harvesting and processing the resulting antibodies made by their immune systems. This makes it expensive. In addition, non-consistent reimbursement policies in different countries as well increase the total cost. Therefore, the high cost of anti-venoms is expected to negatively impact the growth of the market during the forecast period. 

This anti-venom market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Who are the Major Anti-Venom Market Vendors?

The report analyzes the market’s competitive landscape and offers information on several market vendors, including:

 

  • Bharat Serums and Vaccines Ltd.
  • Boehringer Ingelheim International GmbH
  • CSL Ltd.
  • Haffkine bio pharmaceutical Corp. Ltd.
  • Merck KGaA
  • Pfizer Inc.
  • Rare Disease Therapeutics Inc.
  • SERB Sarl
  • Serum Institute of India Pvt. Ltd.
  • VINS Bioproducts Ltd.

 

This statistical study of the anti-venom market encompasses successful business strategies deployed by the key vendors. The anti-venom market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The anti-venom market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies. 

Which are the Key Regions for Anti-Venom Market?

For more insights on the market share of various regions Request for a FREE sample now!

40% of the market’s growth will originate from North America during the forecast period. The US is a key market for anti-venom in North America. However, the market growth rate in this region will be slower than the growth of the market in Asia.

The increasing number of products in the pipeline and the increased focus on R&D activities from both public and private organizations will facilitate the anti-venom market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Type Segments in the Anti-Venom Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The anti-venom market share growth by the polyvalent anti-venom segment will be significant during the forecast period. Polyvalent anti-venoms saves the life of the victim even when the culprit snake is unknown, about 80% of all the time, in the most usual cases, and when a monovalent anti-venom cannot be chosen. Due to such beneficial advantages, polyvalent anti-venoms are the most preferred anti-venom drug. Polyvalent anti-venoms are generally useful in regions where a large number of venomous species are present and when it is difficult to produce monovalent anti-venoms against all of them. With the number of advantages of anti-venoms, key vendors dealing in the anti-venom market are focusing on developing polyvalent anti-venoms. 

This report provides an accurate prediction of the contribution of all the segments to the growth of the anti-venom market size and actionable market insights on post COVID-19 impact on each segment.

 

Anti-Venom Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 7.82%

Market growth 2022-2026

$ 481.51 million

Market structure

Fragmented

YoY growth (%)

7.10

Regional analysis

North America, Asia, Europe, and ROW

Performing market contribution

North America at 40%

Key consumer countries

US, China, Japan, India, and Germany

Competitive landscape

Leading companies, Competitive strategies, Consumer engagement scope

Key companies profiled

Bharat Serums and Vaccines Ltd., Boehringer Ingelheim International GmbH, CSL Ltd., Haffkine bio pharmaceutical Corp. Ltd., Merck KGaA, Pfizer Inc., Rare Disease Therapeutics Inc., SERB Sarl, Serum Institute of India Pvt. Ltd., and VINS Bioproducts Ltd.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Anti-Venom Market Report?

  • CAGR of the market during the forecast period 2022-2026
  • Detailed information on factors that will drive anti-venom market growth during the next five years
  • Precise estimation of the anti-venom market size and its contribution to the parent market
  • Accurate predictions on upcoming trends and changes in consumer behavior
  • The growth of the anti-venom industry across North America, Asia, Europe, and ROW
  • A thorough analysis of the market’s competitive landscape and detailed information on vendors
  • Comprehensive details of factors that will challenge the growth of anti-venom market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch

Read More Read Less

Executive Summary

    Market Landscape

    • Market ecosystem
    • Value chain analysis

    Market Sizing

    • Market definition
    • Market segment analysis
    • Market size 2021
    • Market outlook: Forecast for 2021 - 2026

    Five Forces Analysis

    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition

    Market Segmentation by Type

    • Market segments
    • Comparison by Type
    • Polyvalent anti-venom - Market size and forecast 2021-2026
    • Monovalent anti-venom - Market size and forecast 2021-2026
    • Other anti-venom types - Market size and forecast 2021-2026
    • Market opportunity by Type

    Geographic Landscape

    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2021-2026
    • Asia - Market size and forecast 2021-2026
    • Europe - Market size and forecast 2021-2026
    • ROW - Market size and forecast 2021-2026
    • Key leading countries
    • Market opportunity by geography
    • Market drivers
    • Market challenges
    • Market trends

    Vendor Landscape

    • Vendor landscape
    • Landscape disruption

    Vendor Analysis

    • Vendors covered
    • Market positioning of vendors
    • Bharat Serums and Vaccines Ltd.
    • Boehringer Ingelheim International GmbH
    • CSL Ltd.
    • Merck KGaA
    • Pfizer Inc.
    • Rare Disease Therapeutics Inc.
    • SERB Sarl
    • Serum Institute of India Pvt. Ltd.
    • VINS Bioproducts Ltd.

    Appendix

    • Scope of the report
    • Currency conversion rates for US$
    • Research methodology
    • List of abbreviations

    Research Framework

    Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

    TechnavioINFORMATION SOURCES

    Primary sources

    • Manufacturers and suppliers
    • Channel partners
    • Industry experts
    • Strategic decision makers

    Secondary sources

    • Industry journals and periodicals
    • Government data
    • Financial reports of key industry players
    • Historical data
    • Press releases
    Technavio

    TechnavioDATA ANALYSIS

    Data Synthesis

    • Collation of data
    • Estimation of key figures
    • Analysis of derived insights

    Data Validation

    • Triangulation with data models
    • Reference against proprietary databases
    • Corroboration with industry experts
    Technavio

    TechnavioREPORT WRITING

    Qualitative

    • Market drivers
    • Market challenges
    • Market trends
    • Five forces analysis

    Quantitative

    • Market size and forecast
    • Market segmentation
    • Geographical insights
    • Competitive landscape
    Interested in this report?
    Get your FREE sample now!
    The anti-venom market growth will increase by $481.51 million during 2021-2026.
    The anti-venom market is expected to grow at a CAGR of 7.82% during 2021-2026.
    Technavio has segmented the anti-venom market by type (Polyvalent anti-venom, Monovalent anti-venom, and Other anti-venom types) and geographic (North America, Asia, Europe, and ROW).
    Bharat Serums and Vaccines Ltd., Boehringer Ingelheim International GmbH, CSL Ltd., Haffkine bio pharmaceutical Corp. Ltd., Merck KGaA, Pfizer Inc., Rare Disease Therapeutics Inc., SERB Sarl, Serum Institute of India Pvt. Ltd., VINS Bioproducts Ltd. are a few of the key vendors in the anti-venom market.
    North America will register the highest growth rate of 40.30% among the other regions. Therefore, the anti-venom market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
    • US
    • China
    • Japan
    • India
    • Germany
    The key factors driving the anti-venom market growth are:
    • Rising prevalence of venomous bites and stings
    The anti-venom market vendors should focus on grabbing business opportunities from the polyvalent anti-venom segment as it accounted for the largest market share in the base year.
    Safe and Secure SSL Encrypted
    Technavio

    Single User:

    2500 USD

    Technavio Get the report (PDF) sent to your email within minutes.

    Subscribe & Save

    Get lifetime access to our
    Technavio Insights

    Want to customize this report?

    This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

    We offer $1000 worth of FREE customization at the time of purchase
    Technavio
    Enquire Before Buying
    1. Home
    2. Health Care
    3. Published Report
    17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>